Report Highlights Progress and Priorities Across ESG Initiatives Around the World Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or...
FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...
Bausch & Lomb Corp 0001860742 false 0001860742 2023-04-24 2023-04-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION...
Company-Sponsored Educational Events will Focus on Dry Eye Disease and IC-8® Apthera™ Intraocular Lens Bausch + Lomb Corporation (NYSE/TSX: BLCO...
Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people...
Two New OVDs Offer Surgeons Dual-Action Protection during Cataract Surgery Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a...
Eight Poster Presentations Include Results from 12-Month Safety Extension Trial of Investigational Treatment NOV03 (Perfluorohexyloctane), as...
Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live...
New Technology Provides Cutting Edge Visualization, Ergonomic Positioning and Efficient Workflow Bausch + Lomb, a leading global eye health...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.